One program among several. Metabolic health is a starting point, not the whole platform.

Diabetes, obesity, and metabolic dysfunction are where many members start, and GLP-1 therapy is one tool within a larger cardiometabolic program, managed by a physician with a plan for dose, duration, and what comes after.

The GLP-1 problem

Prescribed fast. Managed rarely.

Cost

GLP-1 and specialty drug spend is accelerating faster than most plans can model or budget for.

Duration

Members are often left on medication indefinitely with no structured plan to reassess or taper.

Side effects

Without a care team monitoring response, side effects go unmanaged and members discontinue on their own.

Foundation

Medication without nutrition, movement, and behavior support rarely holds once a member stops.

The Ciba approach

Optimization first. Deprescribing by design.

A physician manages dose and duration the same way they would any other medication: with a plan for tapering off, not just starting on.

Assess

Clinical evaluation before prescribing

A physician confirms GLP-1 therapy is the right tool for this member’s labs and history before starting.

Optimize

Dose titration and side effect management

Ongoing physician oversight to find the lowest effective dose and manage side effects as they arise.

Support

Nutrition and coaching alongside medication

Registered dietitians and health coaches build the habits that hold after medication is reduced.

Taper

Documented deprescribing pathway

As labs and habits improve, your physician builds a monitored path to reduce or discontinue medication.

Results

A program that shows up in the pharmacy line.

85%

GLP-1 medication burden reduction

44%

Overall pharmacy cost savings

26.4x

Pharmacy ROI, autoimmune cohort

Bring a plan to your GLP-1 spend, not just a discount.

We’ll show you what optimization and deprescribing could mean for your population’s pharmacy trend.